Oncolytics Biotech Inc T.ONC

ONCY P2 Bracelet-1 trial showed pelareorep as sole agent

[Noteable]

https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-updated-randomized-phase-2-data-from-bracelet-1-metastatic-breast-cancer-trial-that-show-pelareorep-driving-robust-increases-in-progression-free-survival-and-confirm/

ONCY P2 Bracelet-1 trial clearly demonstrated pelareorep’s single agent activity.

[Noteable]

Results : Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy   37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with paclitaxel monotherapy   12-month progression-free survival rate of 32.8% for pelareorep-paclitaxel compared to 0% for paclitaxel monotherapy and 0% for

[Noteable]

Pelareorep's ability to target KRAS induces expression of the Fas pathway, reversing early tumor growth, increasing CD8+ T cell infiltration, decreasing myeloid infiltration, the reprogramming of the tumor microenvironment in both early- and late-stage tumors and the elimination of established tumors upon the activation of CD8+ T cells. That's the underlying MOA of pelareorep in the

[Noteable]

The global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022   And with the potential use of pelareorep in combination with a checkpoint and CDK4/6 or PARP inhibitor,  in 2L HR+/HER2- advanced or metastatic breast cancer, in which optimal second-line therapy for hormone receptor-positive

[Noteable]

https://stocktwits.com/Dude1234/message/548432319